Skip to main content
Retour
HAE logo

Haemonetics Corporation

Qualité des données : 100%
HAE
NYSE Healthcare Medical - Instruments & Supplies
58,46 €
▼ 0,12 € (-0,20%)
Cap. Boursière : 2,74B
Fourchette du Jour
58,43 € 59,99 €
Fourchette 52 Semaines
47,32 € 87,32 €
Volume
307 419
Moyenne 50J / 200J
65,06 € / 65,66 €
Clôture Précédente
58,58 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 16,3 0,4
P/B 3,3 2,9
ROE % 18,8 3,8
Net Margin % 12,3 3,9
Rev Growth 5Y % 11,8 10,0
D/E 1,5 0,2

Objectif de Cours des Analystes

Hold
86,60 € +48.1%
Low: 80,00 € High: 94,00 €
P/E Prévisionnel
11,8
BPA Prévisionnel
4,95 €
Croissance BPA (est.)
+0,0%
CA Est.
1,3 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 7,66 €
7,54 € – 7,76 €
1,8 B 3
FY2029 6,90 €
6,79 € – 6,99 €
1,6 B 3
FY2028 5,93 €
5,52 € – 6,17 €
1,5 B 5

Points Clés

Revenue grew 11,82% annually over 5 years — strong growth
Earnings grew 42,64% over the past year
ROE of 18,83% — decent returns on equity
Generating 142,45M in free cash flow
PEG of 0,44 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,87%

Croissance

Revenue Growth (5Y)
11,82%
Revenue (1Y)3,95%
Earnings (1Y)42,64%
FCF Growth (3Y)-6,48%

Qualité

Return on Equity
18,83%
ROIC8,13%
Net Margin12,32%
Op. Margin16,30%

Sécurité

Debt / Equity
1,49
Current Ratio1,62
Interest Coverage22,76

Valorisation

P/E Ratio
16,32
P/B Ratio3,33
EV/EBITDA16,48
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,95% Revenue Growth (3Y) 7,91%
Earnings Growth (1Y) 42,64% Earnings Growth (3Y) 20,54%
Revenue Growth (5Y) 11,82% Earnings Growth (5Y) 20,52%
Profitability
Revenue (TTM) 1,36B Net Income (TTM) 167,68M
ROE 18,83% ROA 6,84%
Gross Margin 57,21% Operating Margin 16,30%
Net Margin 12,32% Free Cash Flow (TTM) 142,45M
ROIC 8,13% FCF Growth (3Y) -6,48%
Safety
Debt / Equity 1,49 Current Ratio 1,62
Interest Coverage 22,76 Dividend Yield 0,00%
Valuation
P/E Ratio 16,32 P/B Ratio 3,33
P/S Ratio 2,01 PEG Ratio 0,44
EV/EBITDA 16,48 Dividend Yield 0,00%
Market Cap 2,74B Enterprise Value 3,65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,36B 1,31B 1,17B 993,20M 870,46M
Net Income 167,68M 117,56M 115,40M 43,38M 79,47M
EPS (Diluted) 3,31 2,29 2,24 0,84 1,55
Gross Profit 778,55M 711,92M 622,87M 530,77M 428,45M
Operating Income 221,82M 164,88M 156,03M 80,75M 89,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,45B 2,20B 1,93B 1,86B 1,82B
Total Liabilities 1,63B 1,24B 1,12B 1,11B 1,09B
Shareholders' Equity 820,84M 959,96M 818,00M 749,42M 731,67M
Total Debt 1,22B 807,79M 765,89M 780,79M 778,28M
Cash & Equivalents 306,76M 178,80M 284,47M 259,50M 192,31M
Current Assets 934,98M 768,90M 769,72M 756,03M 693,55M
Current Liabilities 578,11M 300,38M 251,82M 442,27M 253,50M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#145 of 326
54

Activité Récente

Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026